Skip to main content
Premium Trial:

Request an Annual Quote

Swedish Biosensor Firm Attana Secures ISO Certification


Attana recently announced that it has been certified according to the International Organization for Standardization's 9001:2008 quality management systems standard.

Jesper Isaksson, quality assurance manager at the Stockholm, Sweden-based firm, said in a statement that the certification is a "validation and confirmation" of Attana's quality management processes. Isaksson also noted that since the company's biosensors are used in drug development, it is important that Attana's standards meet ISO requirements.

Founded a decade ago, Attana sells a number of systems for cell and biochemical assays that are run using the company's sensor chips. The chips rely on Attana's Quartz Crystal Microbalance technology, which gauges molecular interaction by measuring vibration frequency changes on the chip's quartz crystal surface as molecules flow over it.

Attana sells a menu of sensor chips optimized to study biomolecules such as proteins, nucleic acids, and carbohydrates; and also binding moieties of different sizes, from peptides to cells.

According to Attana, its ISO certificate is valid for the development and sales of life science analysis systems and associated consultancy services. The certification was carried out over six months by Norske Veritas, a Norwegian classification foundation, Attana said.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.